Recent Company News

• 04:34 PM ET Sep 27, 2026
  

  AFT Pharmaceuticals enters exclusive agreement with Mikasa for development and commercialization of Maxigesic IV for Japan (NZ$4.39, 0.00)

• 02:02 AM ET Sep 24, 2026
  

  Hikma appoints Rebecca Hall as CFO (1595.0000p, 0)

• 02:20 PM ET Sep 10, 2026
  

  Hikma advances its epinephrine nasal spray with multi-market regulatory filings

• 08:07 AM ET Sep 09, 2026
  

  Hikma Pharmaceuticals advances its epinephrine nasal spray with multi-market regulatory filings (1546.0000p, -50)

• 04:30 PM ET Sep 08, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 06:52 AM ET Aug 06, 2026
  

  Media, telecom, banks, energy and utilities outperform; industrials, travel and tech the main laggards:

• 04:14 AM ET Aug 06, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:58 AM ET Aug 06, 2026
  

  StreetAccount Metrics Recap - Hikma Pharmaceuticals H1 Earnings (1571.0000p, 0)

• 02:05 AM ET Aug 06, 2026
  

  Hikma Pharmaceuticals reports H1 Core EPS $1.28 vs consensus $1.12; confirms FY guidance (1571.0000p, 0)

• 05:59 AM ET Aug 05, 2026
  

  StreetAccount Consensus Metrics Preview - Hikma Pharmaceuticals H1 Earnings (15.9000p, +0.09)